2Wolfang M, Karsten M. Solid lipid nanoparticles production, characterization and applications[J]. Adv Drug Deli Revs, 2001,47 (2-3):165.
3Yang SC, Lu LF, Cai Y. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain[J]. J Controlled Release, 1999,59 (3) :299.
4Muller PH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art [J] . Eur J Pharm Biopharm, 2000,50 (1):161.
5Yang SC, Zhu JB, Lu Y. Body distribution of camptothecin solid lipid nanoparticles after oral administration [J]. Pharm Res, 1999, 16 (5):751.
6Lippacher A, Muller RH, Mader K. Preparation of semisolid drug carriers for topical application based on solid lipid nanoparticles[J]. Int J Pharm ,2001,214(1-2) :9.
7Roberta C, C asco MR, Patrizia C.Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin [J]. Int J Pharm, 2002,238 (1 -2):241.
8Foucher SB, Gref R, Pusso P. Design of poly-caprolactone nanospheres coated with bioadhesive hyaluronic acid for ocular delivery[J]. J Controlled Release,2002,83(3) :365.
9Hu FQ, Yuan H, Zhang HH, et al. Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization [J]. Int J Pharm , 2002 , 239 :121.
